Angiodynamics initiates ambition btk rct and registry to advance treatment for critical limb ischemia

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the start of a randomized study of the auryon atherectomy system used in combination with standard balloon angioplasty versus standard balloon angioplasty alone treating infrapopliteal lesions in subjects with criti.
ANGO Ratings Summary
ANGO Quant Ranking